BioTissue® Promotes Diversity and Inclusion in the Workplace

Company’s philosophy of hiring and retaining a diverse and talented workforce contributes to rapid growth 

MIAMI, Fla., March 27, 2014 –BioTissue^®, the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, promotes and supports diversity and inclusion in the workplace, and its philosophy of hiring and retaining a diverse and talented workforce has contributed to rapid growth in a competitive biotech landscape.

BioTissue^® and its parent company TissueTech™ are led by a woman and minority President and CEO Amy Tseng. She and her husband Scheffer C. G. Tseng, MD, PhD, BioTissue^® Chairman and Chief Scientific Officer, founded TissueTech™ and BioTissue^® in 1997 with the vision of advancing the treatment of ocular surface diseases. Since then, the company has grown to 154 employees throughout the United States, 80 percent of whom are minorities. In addition to a woman CEO, nearly half of its management team are women, and its employees come from diverse backgrounds, experiences, and ethnicities.

“We are proud of the talented and diverse group of employees our company has recruited and retained over the years,” said Amy Tseng, President and CEO, TissueTech™ and BioTissue^®. Our company’s credence which has led to our success is to treat everyone with respect and equality, and to provide the same level of opportunity no matter the gender, age or race.”

BioTissue^® continues to experience year to year growth and in January 2014 announced it had attained a 7-year compounded annual growth rate (CAGR) of 35 percent. Due to its rapid growth, in 2013, the company added approximately 40 percent to its workforce. With nearly 200,000 units shipped across all product lines since 2006 and more than 175,000 successful human transplantations, BioTissue^®’s products are used by eye care professionals worldwide to manage ocular surface and lid margin diseases and conditions.

About BioTissue

BioTissue^®, a subsidiary of TissueTech™, is a privately held ophthalmic biologic therapeutics company that develops innovative wound healing and hygiene solutions for the prevention and treatment of ocular surface diseases and disorders. BioTissue^® provides a comprehensive line of cryopreserved amniotic membrane corneal wound healing products, including AmnioGraft^®, a biologic ocular transplantation graft; AmnioGuard^®, a biologic glaucoma shunt tube graft; and the PROKERA^® family of biologic corneal bandage devices. These products incorporate human amniotic membrane processed with the Company’s proprietary CryoTek^® method that ensures the tissue retains its full biologic activity to reduce inflammation, promote healing, minimize corneal scarring and pain, and inhibit the angiogenic process. BioTissue^® also developed and markets Cliradex^®, an all-natural lid, lash and facial cleanser with 4-Terpineol, the most important component of tea tree oil (TTO), for the management of symptoms in lid margin diseases such as blepharitis, demodex, and rosacea. For more information, visit www.biotissue.com.